{"groups":[{"description":"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nRADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV\n\nInternal Radiation Therapy: Undergo brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nExternal Beam Radiation Therapy: Undergo EBRT\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT/EBRT)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Three participants were enrolled into the study between 9/17/2013 and 6/17/2014."}